The stock will trade on the mid-2026 AMPLIFY-7P DFS data readout, not on Q1 financials. With cash runway into Q4 2026, the company is funded through the catalyst. Monitor for any updates on the DFS analysis timing or results.
Price Chart
Executive Summary
Elicio Therapeutics reported Q1 2026 results with a net loss of $11.8M ($0.65 per share), wider than the $11.2M loss in Q1 2025, driven by higher G&A expenses. The company highlighted that the event-driven primary DFS analysis for its Phase 2 AMPLIFY-7P trial of ELI-002 7P in pancreatic cancer is anticipated mid-year 2026, with cash runway extended into Q4 2026 via $13M in ATM proceeds. The filing is neutral as it contains no revenue, no guidance, and the clinical catalyst timeline remains unchanged from prior disclosures.
Key Financial Metrics
Key Facts
- Net loss of $11.8M for Q1 2026 vs $11.2M in Q1 2025
- Net loss per share of $0.65 vs $0.87 in Q1 2025
- Cash and cash equivalents of $14.9M as of March 31, 2026, down from $18.6M at Dec 31, 2025
- Raised $8.0M in Q1 2026 and $5.0M in Q2 2026 via ATM program for total $13.0M
- Event-driven primary DFS analysis for Phase 2 AMPLIFY-7P trial anticipated mid-year 2026
- Cash runway expected into Q4 2026, beyond the anticipated DFS readout
- R&D expenses decreased to $6.8M from $7.8M year-over-year
- G&A expenses increased to $3.8M from $3.0M year-over-year
Financial Impact
Net loss increased by $0.6M year-over-year; cash burn of $3.7M in Q1 2026
Risk Factors
- Phase 2 DFS data may miss expectations or be delayed
- Cash runway depends on no unexpected cost overruns; further dilution possible via ATM
- No revenue; fully dependent on clinical success of ELI-002 7P
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001601485-26-000041 |
| Document: eltx1q26pr.htm | 0001601485-26-000041 |
| Document: 0001601485-26-000041-index-headers.html | 0001601485-26-000041 |
| Document: 0001601485-26-000041-index.html | 0001601485-26-000041 |
| Document: 0001601485-26-000041.txt | 0001601485-26-000041 |
| 8-K Data (Synthetic) | 0001601485-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.83 (−2.66%) |
Sep 22, 2026 5w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.83 (−2.14%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.83 (+43.17%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.83 (+43.17%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.83 (−51.20%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.83 (−61.15%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.83 (−82.65%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.83 (−84.98%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.83 (−85.00%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.83 (+85.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers